NewcelX is a clinical-stage biopharmaceutical company developing off-the-shelf, allogeneic cell therapies derived from human embryonic stem cells (hESCs). The company's lead program, NCEL-101, consists of pancreatic islet-like cell clusters designed to restore natural insulin production in Type 1 Diabetes patients, eliminating the need for external insulin. NewcelX is pursuing multiple delivery strategies for NCEL-101, including portal vein infusion combined with tegoprubart immunosuppression (the most advanced path), omental implantation with immunomodulatory microgels, and subcutaneous implantation via a retrievable scaffold — each designed to solve the central challenge of preventing immune rejection of transplanted cells. NewcelX's second program, AstroRx®, is a cryopreserved astrocyte-based cell therapy targeting ALS, which has received FDA IND approval for a Phase 2a trial. The company's platform uses pluripotent stem cells that can be expanded at industrial scale and stored frozen, enabling scalable manufacturing and global distribution without custom production per patient. NewcelX generates no product revenue and funds operations through equity financing and grants, including cumulative grants from Israel's Innovation Authority. The company contracts manufacturing to Pluri for GMP-grade clinical supply and does not own manufacturing facilities. If products reach commercialization, NewcelX would sell cell therapy doses to hospitals and transplant centers, subject to royalty obligations to academic licensors and grant repayments to the IIA.